News

Gilead Sciences, Inc. and Galapagos NV announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment…
Read More...

Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with ROS1-positive,…
Read More...

Harmony Biosciences, LLC (Harmony) announced that the U.S. Food and Drug Administration (FDA) approved WAKIX (pitolisant) for the treatment of excessive daytime sleepiness (EDS) in…
Read More...

GeneCentric Therapeutics, Inc. announced that it has acquired Select ImmunoGenomics, LLC, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker…
Read More...

Phio Pharmaceuticals Corp. announced that is has entered into a research collaboration with the Helmholtz Zentrum München. The agreement covers the design and development of new targets…
Read More...

Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multi-year Research Collaboration Agreement (RCA) focused on the use of…
Read More...

The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant…
Read More...

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Calquence (acalabrutinib) as a monotherapy treatment for…
Read More...

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced positive results from the Phase III PAOLA-1 trial in women with…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) has approved variations to broaden the use of Imbruvica (ibrutinib) in two…
Read More...

Eli Lilly and Company announced Taltz (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety…
Read More...

AskBio, the world's foremost clinical stage and gene therapy platform company, has acquired Synpromics, the leader in gene control synthetic promoter technology, bioinformatics and…
Read More...

CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced it has entered into a Collaborative Research Agreement (“CRA”) with Yale…
Read More...

Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and…
Read More...

Eidos Therapeutics, Inc. confirmed that it has received a non-binding proposal dated August 8, 2019 from BridgeBio Pharma, Inc., the parent entity of the Company’s majority stockholder,…
Read More...

Onconova Therapeutics announced that they have formed a collaboration to utilize the Mission Bio Tapestri Platform for targeted single-cell DNA analysis to study Onconova’s novel cancer…
Read More...

Oncologie, Inc., a clinical-stage biopharmaceutical company developing innovative oncology treatments targeting the tumor microenvironment, announced that it has entered into a clinical…
Read More...

Jazz Pharmaceuticals plc announced the acquisition of Cavion, Inc. through a merger with a Jazz subsidiary. Under the terms of the agreement, the former Cavion shareholders receive an…
Read More...

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for…
Read More...

RELIEF THERAPEUTICS Holding SA announces that it has executed a binding Share Exchange Agreement (the “Agreement”) with Sonnet BioTherapeutics, Inc. ("Sonnet"). Sonnet is a privately…
Read More...